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Abstract
Purpose of review—In this paper we review the epidemiology, diagnosis and pathogenesis of 
fractures and renal osteodystrophy.
Recent findings—The role of bone quality in the pathogenesis of fracture susceptibility in CKD 
is beginning to be elucidated. Bone quality refers to bone material properties, such as cortical and 
trabecular microarchitecture, mineralization, turnover, microdamage, and collagen content and 
structure. Recent data has added to our understanding of the effects of CKD on alterations to bone 
quality, emerging data on the role of abnormal collagen structure on bone strength, the potential of 
non-invasive methods to inform our knowledge of bone quality and how we can use these methods 
to inform strategies that protect against bone loss and fractures. However, more prospective data is 
required.
Summary—Chronic kidney disease (CKD) is associated with abnormal bone quality and 
strength which results in high fracture incidence.
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Introduction
Chronic Kidney Disease – Mineral and Bone Disorder
The term CKD-mineral and bone disorder (CKD-MBD) was coined by the Kidney Disease 
Improving Global Outcomes (KDIGO) working group to refer more broadly to the systemic 
disorder of mineral and bone metabolism due to CKD; it is manifested by either one or a 
combination of (1) abnormalities of calcium, phosphorus, parathyroid hormone (PTH), or 
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vitamin D metabolism; (2) abnormalities of bone turnover, mineralization, volume, linear 
growth or strength; and (3) vascular or other soft tissue calcification1.
Renal osteodystrophy (ROD) is the bone component of CKD-MBD. It is a disorder of bone 
quality and strength secondary to effects of metabolic and hormonal disturbances that occur 
with kidney failure, including: hyperphosphatemia, hypocalcemia, secondary 
hyperparathyroidism (HPT), 25(OH)D deficiency and decreased renal synthesis of 
1,25(OH)2D, chronic metabolic acidosis, chronic inflammation and premature 
hypogonadism. These abnormalities impair bone turnover and mineralization, collagen 
structure, and cortical and trabecular microarchitecture (Figure 1). Collectively, these effects 
increase fracture risk by reducing both bone mass and quality. Bone “quality” is a catchall 
term for the numerous properties influencing bone’s mechanical function outside of bone 
mass, i.e. if two bones are of the same size but of dissimilar fracture resistance, this 
difference can be attributed to differences in quality.
Fracture epidemiology in chronic kidney disease
Fractures are 2- to 14-fold more common in CKD patients than in the general population2–4, 
and have been reported to increase in prevalence5 and incidence6 as kidney function worsens 
(Figure 2). In patients on dialysis with end stage renal disease (ESRD), fracture incidence at 
the hip was reported to have peaked in 2004 at 21.9 events per 1,000 person-years, with 
subsequent decline to 16.6 per 1,000 person-years in 20107. In contrast, rates of peripheral 
(arm and leg) fractures were reported to have increased continuously between 1992 and 
2009, and the majority of increased fracture risk occurred in Caucasian patients8. Kidney 
transplant recipients are also susceptible to increased fractures9–12: early after 
transplantation hip fracture risk is 34% higher than in patients on dialysis11; risk of hip and 
spine fracture are more than 4- and 23- fold higher12 than in the general population; and 
about 25% of recipients experience a fracture within the 5-years of their transplant9. Recent 
data suggests that improved management of CKD-MBD before and after transplantation 
have resulted in a 3-fold reduction of fracture incidence during the first post-transplant 
year13.
Fractures in CKD patients are associated with excess morbidity, mortality and health 
economic costs14–17. In one study, one-third to almost one-half of patients with ESRD with 
a fracture admission to the hospital were discharged to a skilled-nursing facility. In the year 
following discharge, patients had an adjusted mean of 3.8–5.2 additional hospitalizations, 
comprising on average an extra 33–52 inpatient days compared to patients without 
fracture18. After hip fracture, mortality risk was reported to increase by 16%18 to 60%15, 
and healthcare associated costs have been estimated to exceed $100 and $500 billion for 
patients with ESRD and predialysis CKD respectively17. Therefore, improved identification 
and management of increased fracture risk in CKD patients could significantly reduce both 
the morbidity and economic burdens of CKD-MBD.
CKD impairs bone quality and strength
Bone strength (and fracture risk) is defined by both its mass and quality. Bone mineral 
density (BMD) is a determination of its mass or quantity and is measured in the clinic by 
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dual energy X-ray absorptiometry (DXA). Bone quality is defined by bone material 
properties and includes bone turnover, microarchitecture, mineralization, accumulation of 
microdamage (microscale cracks), and collagen properties (such as glycation and 
crosslinking). The hormonal and metabolic disturbances associated with CKD cause defects 
in all aspects of bone quality (Table 1).
Alterations in bone turnover affect bone strength and quality by controlling bone mass, 
microstructure, and the balance and spatial distribution of newly formed, mature, and aged 
or damaged areas of tissue19. Microdamage, advanced glycation endproducts (AGEs), 
mineralization, mineral carbonate substitution, and mineral crystallinity can all increase or 
accumulate with time and influence bone mechanical properties20, 21. The presence of 
microcracks of sufficient size and/or number is thought to reduce bone’s ability to withstand 
larger impacts22. AGEs form crosslinks in the collagen matrix, limit fibril stretching and 
slipping, and can embrittle the tissue23. Increased mineralization and carbonate substitution 
stiffen the bone matrix and may also contribute to brittleness in older bone24. In healthy 
bone, areas of aged or damaged bone are targeted for turnover, an ongoing repair process 
that removes problem areas and maintains the mean tissue age and properties of the bone. A 
disruption in the balance of turnover, and therefore this repair process, occurs in both high 
and low turnover ROD patients. As such, it is not surprising that bone quality is impaired in 
CKD-MBD. In addition to turnover-related effects on bone quality, CKD may directly affect 
the composition and quality of bone through factors including altered mineral metabolism 
and oxidative stress.
Measurement of Bone Mass
Dual energy X-ray absorptiometry
DXA is the clinical standard to measure bone mass and fracture risk in the general 
population. The use of DXA to predict fractures in patients with CKD has been 
controversial; however, the recent 2016 KDIGO Guideline updates now recommend DXA to 
predict fracture (out for public review). Longitudinal studies in patients with CKD stages 3 
through 5D25–27 and after kidney transplantation28 demonstrated that low areal BMD 
measured by DXA at the forearm, hip (total and femoral neck) and spine predicts future 
fracture. These studies also indicate the World Health Organization T-score cut offs for 
osteopenia and osteoporosis can be used for CKD patients as for the general population. It is 
important to note that DXA does not assess either bone tissue quality or the type of renal 
osteodystrophy; thus, bone biopsy remains the gold standard to inform treatment decisions 
in patients with CKD.
High resolution imaging in CKD-MBD
In addition to DXA discussed above, QCT and HR-pQCT are imaging tools that measure 3-
dimesional bone density and structural aspects of bone quality. They do not measure 
remodeling or mineralization. Therefore, they cannot be used to inform type of treatment 
since they are unable to determine ROD type.
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High-resolution imaging tools assess cortical and trabecular 3-dimensional (volumetric) 
density, geometry, microarchitecture, and strength. They allow us to explore the 
pathogenesis of bone fragility due to CKD or other metabolic bone diseases non-invasively. 
QCT has a resolution of 300 μm3 and quantifies volumetric density and geometry of cortical 
and trabecular bone. Using QCT, studies have found that in CKD patients cortical deficits 
predominate29, 30 and cortical abnormalities both discriminate29 and predict fracture31.
Similarly, HR-pQCT separately quantifies cortical and trabecular volumetric density and 
geometry, but its higher nominal resolution of 60 to 82 μm3 permits measurement of 
trabecular number, thickness and separation. Finite element analysis, a computational 
method to measure bone mechanical competence (i.e., strength), is applied to 3-dimensional 
HR-pQCT datasets to assess biomechanical characteristics of either whole bone or 
individual cortical and trabecular compartments. Advanced HR-pQCT processing methods 
also permit characterization of cortical porosity32, 33 and trabecular plate-rod structure34.
Our group and others have shown that measures of bone density, geometry and 
microarchitecture at the ultradistal radius and tibia from HR-pQCT both discriminated and 
predicted fractures35–39, identified abnormalities in bone quality that negatively impacted 
bone strength40–42, and elucidated underlying microstructural defects that resulted in 
abnormalities of bone density measured by DXA40, 41. For example, in a longitudinal study 
of 54 patients with CKD stages 2 through 5D (ESRD) we found that mean annualized losses 
of bone density by DXA at the radius was 2.9%40. With HR-pQCT, we determined the bone 
loss by DXA was characterized by loss of cortical area (−2.9%), density (−1.3%) and 
thickness (−2.8%) and a significant increase in cortical porosity (+4.2%).
Measurement of Bone Quality
Tetracycline double-labeled transiliac crest bone biopsy with histomorphometry is the 
standard to determine bone quality. Histomorphometric analyses quantify volume and 
microarchitecture of cancellous and cortical compartments, microdamage, characteristics of 
mineralization, turnover, and collagen structure. In CKD, these abnormalities may include 
defects in bone volume and microarchitecture (cortical porosity, thinning and 
trabecularization, and trabecular thinning and dropout); in mineralization (osteomalacia); in 
turnover (low or high turnover); and in collagen structure (accumulation of advanced 
glycation end-products).
Unfortunately, bone biopsy is invasive, expensive, not widely available, and physicians 
performing this procedure require specialized training1, 43, 44. Also the biopsy only provides 
data about the type of ROD at one site (the anterior iliac crest) and at a single time-point. 
Due to these limitations of bone biopsy, non-invasive approaches that can be applied in the 
clinic to diagnose bone disease and monitor treatment responses would be helpful.
Assessing bone turnover and osteomalacia
Because treatment of ROD is based on turnover and the presence or absence of 
osteomalacia, their assessment is essential in determining bone quality in ROD. 
Pharmacologic agents that may prevent fractures in moderate CKD alter remodeling 
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rates45–47. While anti-resorptive agents may be used in patients with high turnover, they 
should not be used in patients with low turnover or adynamic bone disease. Similarly, while 
osteoanabolic agents may be used in patients with low turnover, they are contraindicated in 
patients with high turnover.
Because bone biopsy may not be possible or practical, a non-invasive approach to turnover 
assessment would be helpful. Despite multiple limitations (discussed below), noninvasive 
assessment of remodeling can be achieved with reasonable accuracy by measuring 
circulating levels of parathyroid hormone (PTH) and bone turnover markers (BTMs)48–54. 
Bone formation markers, such as bone specific alkaline phosphatase (BSAP), osteocalcin, 
and procollagen type-1 N-terminal propeptide (P1NP) are markers of osteoblast function. 
Bone resorption markers, such as tartrate-resistant acid phosphatase 5b (Trap-5b) and C-
terminal telopeptides of type I collagen (CTX) are markers of osteoclast number and 
function, respectively.
PTH and BSAP are the most commonly used markers of turnover in CKD-MBD. Generally, 
extremes of PTH predict extremes of bone turnover both in pre-dialysis52 and dialysis-
dependent53, 54 patients. Unfortunately, prediction of underlying histology is poor when 
PTH levels are within the middle range. For BTMs, reference ranges in patients with CKD 
do not exist. Some markers are cleared by the kidney (osteocalcin, P1NP monomer and 
CTX); therefore, their application to ROD diagnostics is challenging. Prediction of ROD 
type can be improved if levels are at the extremes of their ranges. Combing PTH with BTMs 
may also provide diagnostic insight. Low vitamin D levels, and low levels of PTH in 
conjunction with high levels of BSAP have been reported to associate with osteomalacia.
Measurement of PTH and BTMs may have more applicability in the prediction of bone loss 
and fractures than in determining ROD-type27, 36, 40, 41, 55. For example, longitudinal studies 
in CKD patients have shown that high levels of PTH and BTMs predicted loss of cortical 
and trabecular bone and decreases in bone strength40, 41.
In a cross-sectional study of CKD patients, higher levels of PTH and BTMs were associated 
with lower cortical and trabecular density, thinner cortices and trabeculae36, and higher 
levels of BTMs discriminated fracture36. A longitudinal study of ESRD patients found that 
fracture risk was greater in patients with both low (<150 pg/mL) and high (>300 pg/mL) 
PTH levels, and with higher BSAP levels27. In a study of kidney transplant patients PTH 
levels ≥130 pg/mL 3-months after transplantation predicted fractures55. These data indicate 
that higher bone turnover, measured by PTH and BTMs, result in loss of bone density and 
microarchitecture and predict fracture. Longitudinal studies are needed to validate the 
findings of these small studies. Furthermore, longitudinal trends in BTMs have not been 
correlated against changes in bone histology, and correlations between changes in BTMs and 
changes in fracture risk have not been studied.
Can we non-invasively assess bone disease in CKD?
Non-invasive characterization of ROD needs to assess important aspects of bone quality 
(e.g., bone microarchitecture, mineralization and turnover), guide therapeutic choices, and 
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predict clinical outcomes and responses to treatment. Studies have investigated how 
combining bone imaging with markers of bone turnover can assess bone disease severity and 
fracture status, important limitations need to be resolved. Non-invasive tools that identify 
osteomalacia and that accurately define bone turnover are lacking. Furthermore, although we 
know that low BMD and impaired cortical and trabecular microarchitecture predict fracture, 
it is not known whether increases in BMD and improvements in microarchitecture due to 
bone therapies predict decreases in fracture risk. In addition, the best intervals for bone 
disease monitoring has not been established. Thus, in the current era, the decision to treat 
and to monitor treatment response in a CKD patient managed with vitamin D analogs, or 
anti-resorptive or osteoanabolic agents may not be completely possible without a bone 
biopsy.
Biochemistries and DXA are non-invasive measures and provide insight into bone health, 
but neither approach directly tests bone material or mechanical properties. In recent years, 
efforts have been made to develop minimally invasive aproaches to directly probe bone 
material properties through the modification of traditional indentation material testing for in 
vivo use. Two devices, the BioDent (targeted for research) and OsteoProbe (targeted for 
clinical use), use small sharp probes inserted through the skin at the midshaft of the tibia to 
indent the bone surface56, 57. The OsteoProbe has shown promise in distinguishing patient 
populations of differing fracture risk or history58–62, but questions remain regarding the 
interpretation and meaning of the device’s outcome measure, “bone material strength 
index”, or BMSi63. It remains to be seen whether one or both devices will successfully be 
translated to the clinic and if they might provide new insight into bone quality differences in 
CKD patients.
Conclusion
ROD is a complex bone disorder that occurs in patients with kdiney disease and results in 
high risk of fracture. The best method to determine ROD type and overall bone health in 
CKD is bone biopsy. However, bone biopsy is not a practial diagnostic method due to its 
expense and lack of availability. In the office, DXA can classify fracture risk in CKD 
patients, but it cannot be used as a sole method either to assess bone quality or to inform 
therapeutic decisions. Markers of bone remodeling can provide information on turnover 
status and help determine whether treatment with an anabolic or anti-resorptive agent might 
be appropriate. Prospective randomized clinical trials are needed to best assess diagnosis and 
management of CKD-MBD.
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Figure 1. 
35: HR-pQCT provides detailed images of bone geometry and microarchitecture at the radius 
(left) and tibia (right). (A) Scout view represents the reference line position (solid line) and 
the measurement site (dotted line). (B) Images from a healthy, post-menopausal white 
woman. (C) Images from a pre-dialysis female patient with CKD and without fracture. (D) 
Images from a pre-dialysis female patient with CKD and with prevalent fracture.
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Figure 2. 
Hip fracture incidence increases with progressive CKD. As patients age in the general 
population there is an increased incidence of hip fracture. This incidence increases with 
progression of CKD. Data from Alem et al for dialysis patients and the general population 
from Olmstead Minnesota3, Naylor et al for CKD stages 3–45. Pt-yrs = patient years.
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Table 1
Bone changes associated with hormonal and metabolic disturbances of renal osteodystrophy
Decreased bone density and microarchitecture
• Cortical porosity
• Cortical thinning and trabecularization
• Trabecular thinning and dropout
Decreased bone quality
• Mineralization (osteomalacia)
• Abnormal remodeling
adynamic bone disease
low turnover
high turnover
• Microdamage accumulation
• AGE crosslinking
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